Farxiga (far-SEE-guh) for type 2 diabetes will soon hit shelves

Farxiga (far-SEE-guh) for type 2 diabetes will soon hit shelves.

Think of Farxiga (dapagliflozin) as similar to Invokana (canagliflozin). They increase glucose excretion in the urine by inhibiting sodium-glucose co-transporter 2 (SGLT2) in the kidney.

Both lower A1C by about 1%...decrease weight by about 4 to 7 pounds...modestly lower BP...and slightly increase LDL cholesterol.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote